Coverage dated September 21, 2026 to September 25, 2026
FDA panel narrowly backs multi-cancer blood test despite doubts it works
Headline from MedicalXpress, on the newest of 2 developments
A blood test that aims to catch more than 50 types of cancer before symptoms appear narrowly won the backing of U.S. Food and Drug Administration (FDA) advisers Wednesday, even as several doubted it works.
MedicalXpress's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.
Developments in this update
2 dated developments, oldest first, newest marked. Each is named by one outlet's own headline; open its reports to see every outlet that covered it.
FDA panel endorses first-of-a-kind cancer blood test from Grail
Headline from WSVN Miami ·
Newest
FDA panel narrowly backs multi-cancer blood test despite doubts it works
The company Grail says its Galleri blood test can detect up to 50 forms of cancer. An independent panel of experts will decide if the test should be recommended for FDA approval.
WASHINGTON (AP) — A blood test designed to spot signs of multiple cancers in apparently healthy people faces its first major regulatory hurdle Wednesday as advisers to the U.S. government review how well it works. Grail Inc.
A federal health panel has endorsed an experimental cancer test that uses a blood sample to detect multiple forms of the disease. The vote Wednesday from a panel of Food and Drug Administration advisers could pave the way for broader adoption and insurance coverage of the test from manufacturer Grai…
A single blood draw that screens for more than 50 cancers substantially increased cancer detection when added to standard screening, identifying cancers that otherwise might have gone undetected until later stages, according to a new study from the Oregon Health & Science University Knight Cancer In…
A blood test that aims to catch more than 50 types of cancer before symptoms appear narrowly won the backing of U.S. Food and Drug Administration (FDA) advisers Wednesday, even as several doubted it works.
A panel that advises the Food and Drug Administration has recommended it approve the Galleri blood test by biomedical company Grail. The test is designed to search for signals associated with more than 50 cancer types and, when a signal is detected, predicts its likely origin.
Identical headlines usually mean shared wire copy. They are counted as separate articles but are not independent confirmation.
FDA panel narrowly backs multi-cancer blood test despite doubts it works | Since Then
